Post-transfusion Hepatitis Type B: Long Incubation Period and Poor Prognosis in Compromised Hosts

Overview

Journal Gastroenterol Jpn

Specialty Gastroenterology

Date 1989 Apr 1

PMID 2744336

Authors

K Inoue

T Konda

K Takashima

Y Kuwabara

H Sasaki

Affiliations

Soon will be listed here.

Abstract

Seven cases of post-transfusion hepatitis type B [PTH(B)] were investigated. PTH(B) developed in 4 patients more than 65 years old and in 4 patients after treatment of a malignant disease (2 cases of gastric cancer and one each of ovarian cancer and chronic myelogenous leukemia, respectively). The mean incubation period was 78 days (70-90) in patients with non-malignant diseases and 147 days (105-200) in patients with malignant diseases. The symptoms of acute hepatic failure developed in 6 patients and 5 of them expired. One fatal case revealed 4 units of blood and an investigation of 4 donors revealed that one of them was an HBsAg carrier with negative serum HBsAg by the reverse passive hemagglutination (RPHA) method. From these results, it was concluded that compromised hosts such as aged patients or patients with malignant diseases are apt to contract severe PTH(B) with a long incubation period when the transfused blood contains small amounts of HBV.

References

MANNBECK H . The course of infectious hepatitis at varying ages and its spread among different social groups (Stockholm 1948-49). Acta Med Scand. 1956; 155(5):353-9. DOI: 10.1111/j.0954-6820.1956.tb14383.x. View

FENSTER L . Viral hepatitis in the elderly. An analysis of 23 patients over 65 years of age. Gastroenterology. 1965; 49(3):262-71. View

Shimizu M, Ohyama M, Takahashi Y, Udo K, Kojima M, Kametani M . Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis. Gastroenterology. 1983; 84(3):604-10. View

Hoofnagle J, Seeff L, Bales Z, ZIMMERMAN H . Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978; 298(25):1379-83. DOI: 10.1056/NEJM197806222982502. View

Hoofnagle J, Gerety R, Ni L, Barker L . Antibody to hepatitis B core antigen. A sensitive indicator of hepatitis B virus replication. N Engl J Med. 1974; 290(24):1336-40. DOI: 10.1056/NEJM197406132902402. View

Seeff L, Wright E, ZIMMERMAN H, McCOLLUM R . Va cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. Am J Med Sci. 1975; 270(2):355-62. DOI: 10.1097/00000441-197509000-00018. View

Hoofnagle J, Dusheiko G, Schafer D, Jones E, Micetich K, Young R . Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982; 96(4):447-9. DOI: 10.7326/0003-4819-96-4-447. View

McCOLLUM R, Zuckerman A . Viral hepatitis: report on WHO informal consultation. J Med Virol. 1981; 8(1):1-29. DOI: 10.1002/jmv.1890080102. View

Alter H, Holland P, Purcell R, LANDER J, Feinstone S, Morrow A . Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med. 1972; 77(5):691-9. DOI: 10.7326/0003-4819-77-5-691. View

10.

GRADY G, CHALMERS T . RISK OF POST-TRANSFUSION VIRAL HEPATITIS. N Engl J Med. 1964; 271:337-42. DOI: 10.1056/NEJM196408132710702. View

11.

BENNETT H . Hepatitis in the geriatric patient. Geriatrics. 1958; 13(6):345-51. View

12.

Rustgi V, Hoofnagle J, Gerin J, Gelmann E, Reichert C, Cooper J . Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 101(6):795-7. DOI: 10.7326/0003-4819-101-6-795. View

13.

Davis G, Czaja A, Taswell H, Ludwig J, Go V . Hepatitis B virus replication in steroid-treated severe HBsAg-positive chronic active hepatitis. Dig Dis Sci. 1985; 30(2):97-103. DOI: 10.1007/BF01308192. View

14.

Wands J, CHURA C, Roll F, Maddrey W . Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975; 68(1):105-12. View

15.

Scullard G, Smith C, Merigan T, ROBINSON W, GREGORY P . Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology. 1981; 81(6):987-91. View

16.

Sugg U, Erhardt S, Morgenroth T, Flehmig B . Is the use of the term 'posttransfusion hepatitis type B' in its conventional sense still justifiable?. Vox Sang. 1983; 44(5):305-11. DOI: 10.1111/j.1423-0410.1983.tb04487.x. View

17.

Allen J, SAYMAN W . Serum hepatitis from transfusions of blood. Epidemiologic study. JAMA. 1962; 180:1079-85. DOI: 10.1001/jama.1962.03050260001001. View

18.

Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T . Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977; 136(4):571-6. DOI: 10.1093/infdis/136.4.571. View